Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
NCT ID: NCT02817308
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2016-07-31
2020-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These tumor markers were found to be elevated not only in the serum but also in other body fluids in patients with malignant lesions of the parotid gland and the urinary tract. The authors have described in a previews small preliminary study a positive and a strong linear correlation between the levels of CA19-9 in urine and saliva with those presented in the serum of patients with ductal adenocarcinoma of the pancreas. The current study seeks to enlarge the study population to confirm the previous results and standardize the measured levels of CA19-9 in these body fluids.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
NCT02456051
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
NCT02072616
Longitudinal Pancreatic Cancer Study
NCT02250638
Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine
NCT06291779
Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases
NCT02471170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.
intervention: samples of blood, saliva and urine
samples of blood, saliva and urine
Spot samples of Blood, urine and saliva
Control
Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.
intervention: samples of blood, saliva and urine
samples of blood, saliva and urine
Spot samples of Blood, urine and saliva
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
samples of blood, saliva and urine
Spot samples of Blood, urine and saliva
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proven diagnosis of ductal adenocarcinoma of the pancreas
* elevated levels of CA19-9
* possible elevated levels of CEA
Exclusion Criteria
* Previous diagnosis of malignancy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rambam Health Care Campus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Offir Ben-Ishay, MD
Role: PRINCIPAL_INVESTIGATOR
Rambam Health Care Campus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam - health care campus
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA19-90415-15-RMBCTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.